Abstract | BACKGROUND: AIM: METHODS: Thirty-two symptomatic preterm newborns underwent a 24 h pH-MII, during which each baby was fed eight times. Sodium alginate was given four times at alternate meals [ drug-given (DG) vs. drug-free (DF) meals]. Gastro-oesophageal reflux features (i.e. number, acidity, duration and height of gastro-oesophageal reflux) after DG and DF meals were compared by Wilcoxon signed ranks test. RESULTS: CONCLUSIONS: The use of sodium alginate in preterm infants seems to be promising, because this drug decreases gastro-oesophageal reflux acidity and height with the advantage of a nonsystemic way of action and a more favourable safety profile over H2 blockers and PPIs.
|
Authors | L Corvaglia, A Aceti, E Mariani, M De Giorgi, M G Capretti, G Faldella |
Journal | Alimentary pharmacology & therapeutics
(Aliment Pharmacol Ther)
Vol. 33
Issue 4
Pg. 466-70
(Feb 2011)
ISSN: 1365-2036 [Electronic] England |
PMID | 21158879
(Publication Type: Clinical Trial, Journal Article)
|
Copyright | © 2010 Blackwell Publishing Ltd. |
Chemical References |
- Alginates
- Antacids
- Drug Combinations
- Silicic Acid
- Aluminum Hydroxide
- alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination
- Sodium Bicarbonate
|
Topics |
- Alginates
(therapeutic use)
- Aluminum Hydroxide
(therapeutic use)
- Antacids
(therapeutic use)
- Drug Combinations
- Female
- Gastric Acidity Determination
- Gastroesophageal Reflux
(drug therapy)
- Humans
- Hydrogen-Ion Concentration
- Infant
- Infant, Newborn
- Infant, Premature
- Infant, Premature, Diseases
(drug therapy)
- Male
- Silicic Acid
(therapeutic use)
- Sodium Bicarbonate
(therapeutic use)
- Treatment Outcome
|